Zhongtai Securities has reaffirmed its "Buy" rating on HBM HOLDINGS-B (02142). The rating is based on the incremental revenue expected from upfront, near-term payments, and risk-adjusted milestone income related to the out-licensing of HBM7020 and HBM4003. The firm forecasts the company's total operating revenue for 2025-2027 to reach 1.40 billion, 1.59 billion, and 1.49 billion yuan respectively, up from previous estimates of 1.34 billion, 974 million, and 1.03 billion yuan. Net profit attributable to shareholders is projected to be 665 million, 768 million, and 740 million yuan for the same period, compared to prior forecasts of 621 million, 307 million, and 432 million yuan. The key points from Zhongtai Securities' analysis are as follows.
On February 23, 2026, HBM HOLDINGS (02142) announced an exclusive licensing agreement and equity collaboration with Solstice Oncology, a clinical-stage biotechnology company founded by several leading venture capital firms. The agreement grants Solstice Oncology exclusive rights to develop and commercialize the clinical-stage candidate HBM4003, a CTLA-4 antibody, outside Greater China. Under the terms, HBM HOLDINGS will receive total upfront consideration exceeding $105 million, comprising a $50 million cash payment, a $5 million near-term payment, and over $50 million in equity of Solstice Oncology. Additionally, HBM HOLDINGS is eligible for up to approximately $1.1 billion in development, regulatory, and commercial milestone payments based on achieving specific future milestones, plus tiered royalties on net sales outside Greater China.
HBM4003 is the world's first fully human heavy-chain-only antibody to enter clinical stages, positioning it to capitalize on the renewed scientific interest in the CTLA-4 target. Following the awarding of the 2025 Nobel Prize in Physiology or Medicine to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their research on peripheral immune tolerance, CTLA-4, a key regulator of regulatory T-cell function, has regained prominence in immuno-oncology. Generated from HBM HOLDINGS' proprietary Harbour Mice platform, HBM4003 demonstrates enhanced antibody-dependent cellular cytotoxicity activity and exhibits high specificity for clearing Treg cells that highly express CTLA-4 in the tumor microenvironment. Its potent anti-tumor effects, differentiated pharmacokinetic profile, and sustained pharmacodynamic response highlight strong product characteristics. This novel mechanism of action offers potential for improved efficacy and significantly reduced drug toxicity. In Phase I monotherapy trials, HBM4003 showed a favorable safety profile and robust efficacy, with potential indications including melanoma, non-small cell lung cancer, hepatocellular carcinoma, and neuroendocrine tumors among other advanced solid tumors.
The clinical standing of CTLA-4 in MSS colorectal cancer has been strengthened, as evidenced by its inclusion as a Category III recommendation in third-line palliative regimens in the 2025 CSCO Colorectal Cancer Diagnosis and Treatment Guidelines for patients with POLE/POLD1 pathogenic mutations. Recent Phase II clinical data released by the company showed positive efficacy when HBM4003 was combined with tislelizumab in MSS colorectal cancer. In the study involving 24 patients who had received at least two prior lines of therapy, with 66.7% having lung metastases, the objective response rate reached 34.8% and median progression-free survival was 4.2 months. This compares favorably to the 2-3 month PFS typically seen with currently marketed or late-stage CTLA-4 antibodies combined with PD-1 inhibitors in third-line or later colorectal cancer treatment, demonstrating HBM4003's best-in-class potential.
The recent payment package exceeding $105 million will directly supplement the company's cash flow. Combined with the previously announced 2025 profit forecast, which anticipates a profit between $88 million and $95 million, this transaction is expected to further solidify its robust cash position. The cumulative effect of multiple business development activities suggests predictable mid-term growth for the company.
Potential risks include delays in the licensing progress of pipeline drug candidates, slower-than-expected clinical development timelines, and the possibility of information lag or delays in updates from publicly available data used in the research report.
Comments